UCB reports strong performance for first quarter of 2015

UCB has announced its financial results for the first quarter of 2015, during which it delivered a revenue total of 895 million euros (661.44 million pounds).

This represented a year-on-year increase of 19 percent, or 11 percent on a constant currency basis. Key to this success were the core products Cimzia, Vimpat and Neupro, the combined net sales of which rose 36 percent to 433 million euros.

In addition, the company was able to make strong progress with its research and development efforts, commencing a phase III trial for Vimpat in primary generalised tonic-clonic seizures, filing for new regulatory approvals for E Keppra and brivaracetam, and agreeing a new collaboration with Neuropore.

UCB expects the continued growth of Cimzia, Vimpat and Neupro to drive overall growth, with 2015 revenue expected to reach approximately 3.55 to 3.65 billion euros.

Jean-Christophe Tellier, chief executive officer of UCB, said: "UCB had a good start to the year, serving more and more patients living with neurological or immunological diseases."